BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags ... - Nasdaq

Nov 14, 2024 · BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.72 …

CouponFollow Extension

$0.32
OFF

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags ... - Nasdaq

6 days from now

Nov 14, 2024 · BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.72 …

nasdaq.com

36%
OFF

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue ...

6 days from now

Nov 14, 2024 · BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 36% and 82.17%, respectively, for the quarter ended September 2024. Do the numbers hold clues …

zacks.com

$0.32
OFF

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue

6 days from now

BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.72 per share a year …

msn.com

$90
OFF

BioXcel Therapeutics Inc (BTAI) Reports Q3 2023 Financial Results …

6 days from now

Nov 14, 2023 · As of September 30, 2023, BioXcel Therapeutics Inc (NASDAQ:BTAI) had cash and cash equivalents totaling $90.0 million. The company has restructured key financial terms …

yahoo.com

89%
OFF

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

6 days from now

Nov 14, 2024 · BioXcel reports mixed Q3 results with IGALMI revenue at $214K, while achieving 89% YTD growth. Net loss improves substantially as operational costs decrease. ... NEW …

stocktitan.net

$214
OFF

BTAI Stock Price | BioXcel Therapeutics Inc. Stock Quote (U.S.: …

6 days from now

4 days ago · BioXcel Therapeutics Inc Reports Q3 2024 Earnings: Net Revenue at $214K, Net Loss Narrows to $13.7M Nov. 14, 2024 at 7:35 a.m. ET on GuruFocus.com BioXcel …

marketwatch.com

$7
OFF

BioXcel Therapeutics Announces Pricing Of $7M Public Offering

6 days from now

1 day ago · BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript BioXcel announces common stock and warrants offering, no amount given BioXcel Therapeutics …

seekingalpha.com

$4.25
OFF

Bioxcel Therapeutics Stock Price Today (NASDAQ: BTAI) Quote, …

6 days from now

Nov 15, 2024 · BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates. ... (NASDAQ: BTAI) Bioxcel Therapeutics's 52-week high was $4.25, and its 52-week low was …

wallstreetzen.com

$179.05
OFF

BioXcel Therapeutics (BTAI) Earnings Date And Reports 2024

6 days from now

5 days ago · Want to stay updated on the latest earnings announcements and upcoming reports? ... BioXcel Therapeutics (NASDAQ:BTAI) has a recorded net income of -$179.05 million. BTAI …

marketbeat.com

$7
OFF

BioXcel Therapeutics Announces Pricing Of $7.0 Million Public …

6 days from now

NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence …

bioxceltherapeutics.com

$7
OFF

BioXcel Therapeutics Announces Pricing Of $7.0 Million

6 days from now

1 day ago · NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial …

globenewswire.com

$0.32
OFF

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue …

6 days from now

Nov 14, 2024 · BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.72 …

yahoo.com

FAQs about BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags ... - Nasdaq Coupon?

How much did bioxcel Therapeutics (btai) lose?

B ioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.72 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 36%. ...

What is BioXcel Therapeutics (BTAI) doing in 2023?

BioXcel Therapeutics Inc (NASDAQ:BTAI) announced strategic advancements and financial results for the third quarter ended September 30, 2023 in its 8-K filing on November 14, 2023. The company is at the forefront of utilizing artificial intelligence for the development of transformative medicines in neuroscience and immuno-oncology. ...

How much cash did bioxcel Therapeutics use in third quarter 2024?

The Company used $16.3 million in operating cash during the third quarter of 2024. Cash and cash equivalents totaled $40.4 million as of September 30, 2024. BioXcel Therapeutics will host a conference call and webcast today, November 14, 2024, at 8:00 a.m. ET to discuss its third quarter 2024 financial results. ...

Is bioxcel Therapeutics a biopharmaceutical company?

NEW HAVEN, Conn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced its financial results for the third quarter of 2024. ...

Does bioxcel Therapeutics (bxcl501) have a Phase 3 trial?

BioXcel Therapeutics Inc ( NASDAQ:BTAI) has aligned with FDA recommendations to conduct a Phase 3 trial for its TRANQUILITY program, which evaluates BXCL501 for the acute treatment of agitation associated with Alzheimer's dementia. ...

What was the closing price of bioxcel Therapeutics Inc registered SHS?

On Thursday 08/22/2024 the closing price of the BioXcel Therapeutics Inc Registered Shs share was $0.65 on BTT. Compared to the opening price on Thursday 08/22/2024 on BTT of $0.67, this is a drop of 2.47%. BioXcel Therapeutics Inc Registered Shs's market capitalization is $27.14 M by 40.74 M shares outstanding. ...